Agomab to acquire Origo Biopharma

Sunday 14 November 2021


Agomab Therapeutics NV is to acquire Origo Biopharma SL of Spain for an undisclosed sum in order to advance its strategy of targeting growth factor signalling pathways for the development of new therapies. The acquisition comes less than a year after Agomab, which is based in Belgium, raised $74 million in a Series B financing round led by Redmile Group of San Francisco, with participation from Cormorant Asset Management LLC of Boston, US.